Stephens Inc. AR Sells 23 Shares of Axon Enterprise, Inc $AXON

Stephens Inc. AR decreased its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 0.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,000 shares of the biotechnology company’s stock after selling 23 shares during the quarter. Stephens Inc. AR’s holdings in Axon Enterprise were worth $2,484,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in shares of Axon Enterprise by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock worth $4,540,005,000 after purchasing an additional 185,571 shares in the last quarter. Alliancebernstein L.P. increased its holdings in shares of Axon Enterprise by 15.9% in the 1st quarter. Alliancebernstein L.P. now owns 1,284,935 shares of the biotechnology company’s stock worth $675,812,000 after purchasing an additional 175,890 shares in the last quarter. Westfield Capital Management Co. LP increased its holdings in shares of Axon Enterprise by 29.8% in the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock worth $487,977,000 after purchasing an additional 212,931 shares in the last quarter. Northern Trust Corp increased its holdings in shares of Axon Enterprise by 1.2% in the 1st quarter. Northern Trust Corp now owns 725,720 shares of the biotechnology company’s stock worth $381,692,000 after purchasing an additional 8,794 shares in the last quarter. Finally, Jennison Associates LLC increased its holdings in shares of Axon Enterprise by 23,203.7% in the 1st quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock worth $322,961,000 after purchasing an additional 611,418 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on AXON shares. Wolfe Research started coverage on Axon Enterprise in a report on Monday, July 7th. They issued an “outperform” rating for the company. Craig Hallum upgraded Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 price objective for the company in a research report on Tuesday, August 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Axon Enterprise in a research report on Wednesday, October 8th. Piper Sandler began coverage on Axon Enterprise in a research report on Tuesday, September 23rd. They set an “overweight” rating and a $893.00 price objective for the company. Finally, Northland Securities set a $800.00 price objective on Axon Enterprise in a research report on Tuesday, August 5th. Fourteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $841.64.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, CFO Brittany Bagley sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $713.88, for a total transaction of $3,569,400.00. Following the sale, the chief financial officer directly owned 93,592 shares in the company, valued at $66,813,456.96. This represents a 5.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Patrick W. Smith sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 7th. The shares were sold at an average price of $713.74, for a total value of $7,137,400.00. Following the sale, the chief executive officer owned 3,033,982 shares in the company, valued at approximately $2,165,474,312.68. This trade represents a 0.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 59,932 shares of company stock valued at $45,115,616. Corporate insiders own 4.40% of the company’s stock.

Axon Enterprise Trading Down 0.8%

Shares of AXON stock opened at $701.09 on Thursday. Axon Enterprise, Inc has a 1 year low of $422.38 and a 1 year high of $885.91. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71. The stock’s 50 day simple moving average is $734.21 and its two-hundred day simple moving average is $720.68. The company has a market cap of $55.04 billion, a PE ratio of 173.11, a price-to-earnings-growth ratio of 27.46 and a beta of 1.41.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The business had revenue of $668.54 million for the quarter, compared to the consensus estimate of $641.77 million. During the same period in the prior year, the business posted $1.20 earnings per share. The company’s quarterly revenue was up 32.6% compared to the same quarter last year. Axon Enterprise has set its FY 2025 guidance at EPS. Research analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.